Background: A big pharmaceutical company approached Aurigene Pharmaceutical Services for manufacturing an activated mPEG derivative. The process involved 11 stages. Three major chain stages and eight intermediate steps. Challenges: Stage-1 and 2 reactions are sluggish and observed unreacted starting materials which is difficult to purify. Only 10-20% product formation observed in stage-3. Stage-3 product was unstable under reaction conditions and during isolation. The key intermediate is not commercially available and involves complex chemistry.
Aurigene solution: Optimized the mole equivalents of reagents in all stages to drive the reaction for completion, which helped to avoid carryover of impurities to final stage. Screened multiple bases/solvents/temperature for stage 3 and ensured the completion of reaction. Identified suitable isolation and storage conditions (-20°C) to avoid the stage-3 product degradation. Optimized the final stage reaction & purification process to achieve>90% purity.Appropriate optimization of the parameters helped in successful scale up of side chain (key intermediate). Outcome:
Contact Us
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market